A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 300+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №10 · week of Sep 6, 2026See the trends →
Top journals this week: Nat Rev Gastro Hep / Nature Medicine / J Hepatology / Gastroenterology
Selectivity
7.1%
22 in the issue of 308 screened
in the issue 22in depth 79held 11filtered out 196
92.9% of what published this week did not make the issue. That filter is the product. A further 79 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 21 of the 22 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. Click a segment to filter the issue.
The signal map
637791narrative reviewguideline →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version

naltrexone triples abstinence (64% vs 22%) in compensated alcohol cirrhosis with AUD, use MPS for postcholecystectomy strictures, FCSEMS for chronic pancreatitis, and balloon dilation for PSC strictures, and IBD CRC surveillance should prioritize patients with ≥2 affected relatives over early-onset family history.

The 22 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 79 more, read and scored the same way, in one line each at the foot of the issue.

Your subspecialty, the takeaways
IBD24Hepatology30Esophagus/Reflux5Pancreas/Biliary10Endoscopy15Motility6Colorectal9Nutrition2
Type

This week to know

the 11 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
Hepatology rct · n=100 · Sep 1, 2026 · Liver International · IF 6.7

Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial.

New therapyalcohol-associated liver diseasecirrhosis
Clinical takeawayConsider naltrexone 50 mg/day for patients with compensated alcohol-associated cirrhosis (CTP ≤6, MELD ≤13) and alcohol use disorder, alongside psychosocial support, to improve abstinence and reduce craving compared to placebo. Adverse events were comparable between groups.
What it foundNaltrexone (50 mg/day) achieved 64% abstinence at 12 weeks vs 22% with placebo (OR 10.86, 95% CI: 1.89-62.2) and reduced craving scores (OCDS-O 6.63 vs 9.29, p < 0.01; OCDS-C 6.35 vs 9.02, p < 0.01) in compensated alcohol-associated cirrhosis.
ContextFirst RCT to demonstrate safety and efficacy of naltrexone in compensated alcohol-associated cirrhosis, addressing a prior gap where no pharmacotherapy was approved due to liver safety concerns.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.

Decision at stakepharmacological management of alcohol use disorder in compensated alcohol-associated cirrhosis

… Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. … Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.

American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211. · reviewed 2026-07-23 ↗
Alla M … Sarin SK · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Endoscopy guideline · Sep 3, 2026 · Endoscopy · IF 11.8

Biliary stricture management: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Guideline / reviewbiliary strictureERCPguideline
Clinical takeawayFollow ESGE guidelines for stent selection and management in biliary strictures: use MPS for postcholecystectomy strictures, FCSEMS for chronic pancreatitis strictures (6-12 months) when >2 cm from hepatic confluence, and balloon dilation alone for PSC strictures (avoid stenting). Avoid USEMS for unconfirmed etiology. For hilar malignant obstruction, use ERCP for Bismuth types I-II and ERCP/EUS-BD for Bismuth III-IV over PTBD.
What it foundESGE provides specific stent and dilation recommendations for benign and malignant biliary strictures, including MPS for postcholecystectomy strictures, FCSEMS for chronic pancreatitis strictures (6-12 months) when located >2 cm distally from the main hepatic confluence, and balloon dilation alone for PSC strictures (no added benefit of stenting, which may increase adverse events). Avoid USEMS for unconfirmed etiology and prefer ERCP over PTBD for hilar malignant obstruction (Bismuth types I-II). For Bismuth III-IV, ERCP or combined ERCP/EUS-BD is preferable over primary PTBD.
ContextRefines and standardizes current practice with evidence-based recommendations for stent use and drainage strategies across various biliary stricture etiologies, including location-specific and population-specific guidance.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

Decision at stakethe management of benign biliary strictures with multiple plastic stents or FCSEMS

… Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. … High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Lemmers A … Triantafyllou K · Endoscopy · IF 11.8 · PubMed ↗Permalink
IBD prospective cohort · n=1,338,028 · Sep 3, 2026 · Gastroenterology · IF 25.1

Impact of Family History on Colorectal Cancer Risk in Inflammatory Bowel Disease and in Matched General Population Comparators.

New evidencecolorectal cancerepidemiology
Clinical takeawayRe-evaluate surveillance prioritization for IBD patients, focusing on those with ≥2 first-degree relatives with CRC (any age) rather than solely early-onset family history.
What it foundIn IBD, CRC incidence was highest with ≥2 affected first-degree relatives (2.69 additional cases/1,000 person-years vs no family history), while early-onset CRC heredity showed minimal risk increase (0.42/1,000 person-years). CRC risk was comparable between IBD patients and general population with the same family history, except in those without family history where IBD conferred higher risk.
ContextChallenges current guideline focus on early-onset CRC family history, showing multiple affected relatives confer greater absolute risk in IBD, with similar risk patterns to the general population when family history is present.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeroutine endoscopic CRC surveillance in Crohn's colitis

… DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes MILD-TO-MODERATE.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Everhov ÅH … Olén O · Gastroenterology · IF 25.1 · PubMed ↗Permalink
Motility rct · n=30 · Sep 1, 2026 · Gastroenterology · IF 25.1

Individualized targeted exclusion diet based on confocal laser endomicroscopy does not improve irritable bowel syndrome symptoms: a randomized controlled crossover trial.

New evidenceIBSbiomarker
Clinical takeawayDo not use confocal laser endomicroscopy (CLE) to guide dietary exclusions in IBS: CLE findings lack specificity for food triggers and do not predict dietary response.
What it foundIndividualized exclusion diets based on CLE-identified food triggers did not improve IBS symptoms more than sham diets (42% vs 36% response, OR=1.33, p=0.6), and CLE-detected mucosal alterations occurred in 100% of healthy controls, indicating poor specificity for food triggers.
ContextChallenges prior uncontrolled studies suggesting CLE-guided diets improve IBS symptoms, showing no benefit over sham exclusion in a controlled trial involving IBS patients.
Reinforcessuggested applicable standard· American Gastroenterological Association, Chey WD, Hashash JG, Manning L, Chang L. "AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review." Gastroenterology. 2022;162(6):1737-1745 (doi:10.1053/j.gastro.2021.12.248; PMID 35337654)

Decision at stakewhether to use confocal laser endomicroscopy to identify food triggers for IBS

… The low-FODMAP diet is currently the most evidence-based diet intervention for IBS and is delivered as a structured 3-phase protocol, NOT lifelong restriction: (1) restriction of high-FODMAP foods lasting NO MORE than 4-6 weeks, (2) reintroduction of FODMAP foods, and (3) personalization based on reintroduction results. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Per AGA best practice advice: dietary intervention is most appropriate for IBS patients who have insight into meal-related symptoms and are motivated to make dietary changes. Soluble fiber (e.g., psyllium/ispaghula) is efficacious for global IBS symptoms and is a reasonable initial option, most suitable in constipation-predominant IBS; insoluble fiber (wheat bran) is NOT. The low-FODMAP diet is currently the most evidence-based diet intervention for IBS and is delivered as a structured 3-phase protocol, NOT lifelong restriction: (1) restriction of high-FODMAP foods lasting NO MORE than 4-6 weeks, (2) reintroduction of FODMAP foods, and (3) personalization based on reintroduction results. Any specific diet intervention should be attempted for a predetermined length of time; if there is no clinical response, the diet should be ABANDONED and a different diet or therapy tried, rather than continued indefinitely. Refer willing and appropriate patients to a GI registered dietitian nutritionist (RDN) to implement and supervise the diet. Poor candidates for restrictive diet interventions include patients who already consume few culprit foods, those at risk for malnutrition, those who are food insecure, and those with an eating disorder or uncontrolled psychiatric disorder; routine screening for disordered eating/eating disorders by careful dietary history is critical before starting a restrictive diet.

American Gastroenterological Association, Chey WD, Hashash JG, Manning L, Chang L. "AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review." Gastroenterology. 2022;162(6):1737-1745 (doi:10.1053/j.gastro.2021.12.248; PMID 35337654) · reviewed 2026-07-19 ↗
Balsiger LM … Tack J · Gastroenterology · IF 25.1 · PubMed ↗Permalink
Colorectal guideline · Sep 1, 2026 · Am J Gastro · IF 9.8

ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes.

Guideline / reviewguidelinefamilial adenomatous polyposiscolorectal cancer
Clinical takeawayFollow updated guideline recommendations for risk assessment (personal/family history), genetic testing (modality/timing), and cancer risk mitigation (endoscopic/surgical interventions) in patients with suspected or confirmed hereditary adenomatous polyposis syndromes.
What it foundGuidelines outline risk assessment, genetic testing, and endoscopic/surgical management strategies for hereditary adenomatous colorectal polyposis syndromes (FAP and MAP) to reduce cancer incidence and mortality.
ContextUpdates prior guidelines with new evidence on genetic testing, management strategies, and cancer risk mitigation for FAP and MAP.
Measured against the standard of care· ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.)

Decision at stakethe timing and modality of genetic testing and surveillance in hereditary adenomatous polyposis syndromes

… For polyposis, it replaces the 2015 ACG hereditary GI cancer guideline (Syngal et al.), Recommendations 10-11. … Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Polyposis syndromes are now governed by ACG 2026 (Mankaney G, Idos GE, Stoffel EM, Weiss JM, Shah S, Qayed E, Harnegie MP, Burke CA; Am J Gastroenterol 2026;121(9):2086-2120, GRADE). For polyposis, it replaces the 2015 ACG hereditary GI cancer guideline (Syngal et al.), Recommendations 10-11. Germline multigene panel testing is recommended for anyone with 20 or more cumulative lifetime colorectal adenomas (strong recommendation) and suggested for 10-19 adenomas (conditional, because the yield is lower). The 2015 polyposis testing trigger was more than 10 adenomas. Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. Colonoscopy then repeats every 1-3 years depending on the histology, size and number of polyps. It moves to every 3-6 months when there are many or large polyps, or high-grade dysplasia. This replaces the 2015 schedules of annual sigmoidoscopy/colonoscopy from puberty for classic FAP, colonoscopy every 1-2 years from the late teens for AFAP, and from age 25-30 for MAP. Whether at-risk children in classic-FAP families still start younger is not stated in the excerpt available at review; confirm against the full text. For FAP, AFAP and MAP, upper endoscopic surveillance that includes viewing the duodenal papilla is suggested over no surveillance (Recommendation 8, conditional). Duodenal management is still staged by Spigelman, which has acknowledged limits in sensitivity for duodenal and papillary cancer. The 2026 starting age and intervals for upper endoscopy are not stated in the excerpt available at review. The choice of operation (total colectomy with IRA, IPAA, or end ileostomy) is individualized by genotype, polyp distribution, cancer status, comorbidity and preference, with early referral to an experienced colorectal surgeon. IRA is generally favored with up to about 20 rectal adenomas and IPAA above that, though this is not a fixed cutoff. The rectum or pouch should be checked endoscopically every year after IRA or IPAA. Chemoprevention is recommended against as a substitute for colectomy when surgery is indicated. Whether 2026 keeps annual thyroid ultrasound is not stated in the excerpt available at review. Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.) · reviewed 2026-10-11 ↗
Mankaney G … Burke CA · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal retrospective · n=110,410 · Sep 3, 2026 · Am J Gastro · IF 9.8

Longitudinal Data from a Large, Multi-Target Stool DNA Colorectal Cancer Screening Program.

New evidencecolorectal cancer screeningbiomarkerartificial intelligencehealth services
Clinical takeawayPrioritize colonoscopy follow-up within 6 months after a positive mt-sDNA test to maximize advanced adenoma detection, and address system-level barriers to repeat mt-sDNA testing every 3 years after a negative result, as only 35.3% adhered to repeat testing.
What it foundColonoscopy after positive mt-sDNA had a 30.7% advanced adenoma yield and 1.3% adenocarcinoma yield, exceeding specialty society benchmarks (adenoma detection rate >50%). Longer intervals (>6 months) to colonoscopy were associated with higher advanced adenoma detection (trend P=0.001).
ContextConfirms mt-sDNA as a high-yield screening tool but highlights critical gaps in follow-up (65.1% completion within 12 months) and repeat testing adherence (35.3% within 3 years), which undermine program effectiveness.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

Decision at stakethe clinical decision to use mt-sDNA as a screening tool for colorectal cancer

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Garg SK … Chaudhary R · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal meta analysis · Sep 1, 2026 · Clin Gastro Hep · IF 16.2

Prevalence and Progression of Subtypes of Gastric Premalignant Lesions: A Systematic Review & Meta-Analysis.

New evidenceepidemiologymeta-analysissystematic reviewbiomarker
Clinical takeawayConsider subtyping gastric precancerous lesions (complete vs incomplete IM, LGD vs HGD) during endoscopy to inform risk-stratification, particularly in patients with incomplete IM or HGD, acknowledging current guidelines already recommend this approach.
What it foundIncomplete gastric intestinal metaplasia (IM) progresses to gastric cancer at 12.15 per 1000 person-years vs 1.73 for complete IM (p <0.01); high-grade dysplasia (HGD) progresses at 344.48 per 1000 person-years vs 11.55 for low-grade dysplasia (LGD, p <0.01), though estimates have substantial heterogeneity.
ContextThe literature reports a systematic review and meta-analysis on the prevalence and progression of subtypes of gastric premalignant lesions, but no consensus on colorectal health was identified in the provided signals.
Refinessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34)

Decision at stakerisk stratification of gastric intestinal metaplasia and dysplasia subtypes

… Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform individual gastric risk assessment and staging of precancerous conditions at first-time gastroscopy, irrespective of the patient's country of origin. Use high quality endoscopy with virtual chromoendoscopy (VCE), after proper training, for screening, diagnosis and staging of atrophy and intestinal metaplasia and after endoscopic therapy; VCE guides the biopsy site, with random biopsies taken only when there are no endoscopically suspected changes. Take biopsies from at least two topographic sites, 2 from the antrum/incisura and 2 from the corpus, VCE-guided, in two separate, clearly labeled vials; an additional incisura biopsy is optional, not required. Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. Eradicate H. pylori in all patients with precancerous conditions and after endoscopic or surgical therapy. Discontinue or do not start gastric cancer screening or surveillance in asymptomatic individuals over 80, and weigh comorbidities when planning treatment of superficial lesions. Advise smoking cessation; low-dose daily aspirin may be considered for gastric cancer prevention only in selected individuals already at high cardiovascular risk. For visible neoplasia, use ESD for differentiated lesions clinically staged as dysplastic (low or high grade) or intramucosal carcinoma (any size if not ulcerated, or ≤30 mm if ulcerated), with EMR an alternative for Paris 0-IIa lesions ≤10 mm with low likelihood of malignancy. At the population level, endoscopic screening is suggested every 2-3 years in high-risk regions (age-standardized rate >20 per 100,000 person-years), every 5 years in intermediate-risk regions (ASR 10-20) only if cost-effectiveness has been proven, and not at all in low-risk regions (ASR <10).

European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34) · reviewed 2026-07-23 ↗
Grell Y … Laszkowska M · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Nutrition rct · n=163 · Sep 3, 2026 · Clin Gastro Hep · IF 16.2

STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure.

New therapyshort bowel syndromeparenteral nutritionenteral nutrition
Clinical takeawayConsider once-weekly subcutaneous apraglutide for SBS-IF patients, particularly those with stoma anatomy, to reduce PS dependence, noting its favorable safety profile.
What it foundApraglutide significantly reduced weekly PS volume by 25.5% vs 12.5% with placebo at 24 weeks in SBS-IF patients, with a greater effect in the stoma subgroup (-25.6% vs -7.8%).
ContextConfirms and extends phase 2 findings, showing apraglutide's efficacy in reducing PS requirements in a larger, global phase 3 trial.
Refinessuggested applicable standard· ESPEN (European Society for Clinical Nutrition and Metabolism), "ESPEN guideline on chronic intestinal failure in adults, Update 2023," Clinical Nutrition, 2023

Decision at stakeconsidering GLP-2 analogs to reduce parenteral support in SBS-IF

… In carefully selected PN-dependent patients, and only when prescribed by clinicians experienced in SBS/IF management (generally once the adaptation phase is complete), consider the GLP-2 analog teduglutide (0.05 mg/kg/day subcutaneously) to promote intestinal adaptation and reduce PN volume, but only after baseline screening to exclude neoplasia and contraindications (colonoscopy with removal of any polyps when colon and/or rectum is present, and assessment for active or recent [within 5 years] gastrointestinal, hepatobiliary, or pancreatic malignancy, which contraindicate its use) and with mandatory ongoing safety monitoring (surveillance colonoscopy after 1-2 years then every 5 years, plus vigilance for colorectal/GI polyps and neoplasia, intestinal obstruction, biliary/gallbladder and pancreatic disease, and fluid overload); add antimotility agents (loperamide, then codeine/opium tincture) for high-output stoma, and provide lifelong nutrient surveillance/supplementation (notably B12) plus monitoring for CRBSI, IFALD, oxalate stones, and refeeding syndrome.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Manage short bowel syndrome / intestinal failure with a multidisciplinary IF team using a three-phase nutrition strategy: initiate TPN with IV hydration and electrolyte replacement in the acute hypersecretory phase, progressively advance enteral feeds and wean PN during the 1-2 year adaptation phase, then maintain an oral diet with selective PN as needed. In carefully selected PN-dependent patients, and only when prescribed by clinicians experienced in SBS/IF management (generally once the adaptation phase is complete), consider the GLP-2 analog teduglutide (0.05 mg/kg/day subcutaneously) to promote intestinal adaptation and reduce PN volume, but only after baseline screening to exclude neoplasia and contraindications (colonoscopy with removal of any polyps when colon and/or rectum is present, and assessment for active or recent [within 5 years] gastrointestinal, hepatobiliary, or pancreatic malignancy, which contraindicate its use) and with mandatory ongoing safety monitoring (surveillance colonoscopy after 1-2 years then every 5 years, plus vigilance for colorectal/GI polyps and neoplasia, intestinal obstruction, biliary/gallbladder and pancreatic disease, and fluid overload); add antimotility agents (loperamide, then codeine/opium tincture) for high-output stoma, and provide lifelong nutrient surveillance/supplementation (notably B12) plus monitoring for CRBSI, IFALD, oxalate stones, and refeeding syndrome.

ESPEN (European Society for Clinical Nutrition and Metabolism), "ESPEN guideline on chronic intestinal failure in adults, Update 2023," Clinical Nutrition, 2023 · reviewed 2026-07-23 ↗
Joly F … STARS Investigators · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology prospective cohort · n=16,560 · Sep 1, 2026 · Liver International · IF 6.7

Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.

New evidencealcohol-associated liver diseaseepidemiology
Clinical takeawayCounsel patients with steatotic liver disease (SLD), especially females with ALD, on the significant mortality risk associated with alcohol use and emphasize the need for ongoing alcohol cessation support. Monitor and reassess alcohol consumption and SLD subtype at regular intervals, as classifications can change over time.
What it foundIn a longitudinal cohort of adults aged 45-85 years, ALD showed the highest mortality risk (aHR 6.11; 95% CI 1.76-21.19), with females having higher mortality rates than males (11.37 vs. 5.60 per 1000 person-years).
ContextThis study challenges the reliance on static SLD classifications by demonstrating that disease phenotypes and associated mortality risks are dynamic, with substantial transitions between subtypes over time in a longitudinal cohort.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

Decision at stakethe recommendation to limit alcohol intake in MASLD/MetALD patients

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. … MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Rapino C … Saeed S · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatology prospective cohort · n=1,531 · Sep 2, 2026 · Dig Liver Dis · IF 4.2

Comparative performance of HCC risk scores in identifying low-risk patients with cirrhosis: A multicenter cohort study.

New evidencecirrhosishepatocellular carcinomabiomarkerepidemiology
Clinical takeawayConsider using THRI over aMAP to identify cirrhosis patients with truly low HCC risk (0.5% 5-year risk) who may safely defer surveillance, particularly in non-viral etiologies (60% of cohort).
What it foundTHRI identified low-risk cirrhosis patients (18% of cohort) with a 0.5% 5-year HCC risk vs 2.9% for aMAP low-risk patients, and had higher discrimination than aMAP (AUC 0.74 vs 0.64 at 3 years).
ContextChallenges current reliance on aMAP for HCC risk stratification in cirrhosis, particularly for non-viral etiologies in a Western cohort.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)

Decision at stakeidentifying low-risk cirrhosis patients who may not need HCC surveillance

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. … AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.

AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834) · reviewed 2026-10-25 ↗
Moussa M … Sonneveld MJ · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Hepatology rct · n=87 · Sep 3, 2026 · J Gastro Hep · IF 3.5

A Novel Anchoring Catheter Improves the Success, Efficiency, and Satisfaction of Paracentesis in Refractory Ascites: A Multicenter Randomized Crossover Trial.

New therapyasciteshealth servicesbasic science
Clinical takeawayConsider using the KH anchoring catheter instead of conventional angiocatheters for repeated paracentesis in cirrhotic patients with refractory ascites, given its higher success rate and shorter procedure time without increased adverse events.
What it foundThe novel anchoring catheter (KH) increased paracentesis success to 87.5% vs 71.6% with conventional angiocatheter (OR 2.78) and reduced median procedure time by 9 minutes (71 vs 80 min). Adverse events were comparable, with no major complications.
ContextChallenges the conventional angiocatheter by demonstrating superior efficacy and efficiency in a randomized crossover trial, without increased adverse events.
Measured against the standard of care· AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557)

Decision at stakethe choice of catheter for large volume paracentesis in refractory ascites

Perform a diagnostic paracentesis as soon as possible in any patient with new-onset ascites that can be sampled. Also perform one in any patient with cirrhosis and ascites who is admitted to hospital. … Paracentesis is safe with coagulopathy: INR >1.5 or platelets <50×10^9/L is not a contraindication, and routine FFP or platelet transfusion is not recommended. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform a diagnostic paracentesis as soon as possible in any patient with new-onset ascites that can be sampled. Also perform one in any patient with cirrhosis and ascites who is admitted to hospital. AASLD 2021 says this applies to emergent admission for any reason. AGA 2025 BPA 2 names admission for ascites- or encephalopathy-related symptoms. The tap rules out SBP even without signs of infection, because up to one-third of SBP is asymptomatic. Repeat it whenever signs, symptoms or labs suggest infection, and in tense ascites with AKI. Paracentesis is safe with coagulopathy: INR >1.5 or platelets <50×10^9/L is not a contraindication, and routine FFP or platelet transfusion is not recommended. Possible exceptions are DIC, and uremia with thrombocytopenia, where desmopressin may be considered. Initial fluid testing: neutrophil (PMN) count, total protein, and ascitic albumin with a same-day serum albumin to calculate the SAAG. AGA 2025 adds Gram stain and culture to the initial panel for new-onset ascites and hospitalized patients. AASLD 2021 treats culture as part of the SBP workup rather than the routine panel. Either way, inoculate ≥10 mL into aerobic and anaerobic blood-culture bottles at the bedside before antibiotics. Amylase, cytology, glucose, LDH, AFB/ADA and triglycerides are ordered only for a clinical reason. SAAG ≥1.1 g/dL means portal hypertension (~97% accuracy). SAAG <1.1 g/dL points to a non-portal-hypertensive cause: carcinomatosis, TB peritonitis, nephrotic syndrome, pancreatic or chylous ascites. Within high-SAAG ascites, total protein <2.5 g/dL suggests cirrhosis (also massive liver metastases or late Budd-Chiari). Total protein ≥2.5 g/dL suggests a cardiac or postsinusoidal cause (heart failure, portal vein thrombosis, SOS, early Budd-Chiari), so work up with echocardiography, hepatic-vein Doppler or right-heart catheterization. SBP is diagnosed by ascitic PMN >250/mm^3, with or without a positive culture, once a surgically treatable source has been excluded. SBE is diagnosed by pleural fluid PMN >250/mm^3 in a hepatic hydrothorax after pneumonia and other secondary causes are excluded. It is treated with antibiotics and no chest tube.

AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557) · reviewed 2026-10-11 ↗
Jeon SH … Kim SG · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink

The read

the next 11, in full

IBD· 4

IBD meta analysis · n=9,902 · Sep 1, 2026 · Inflamm Bowel Dis · IF 4.5

Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.

New evidenceJAK inhibitorssystematic reviewmeta-analysis
Clinical takeawayCounsel IBD patients starting JAK inhibitors, especially upadacitinib or pediatric cases, about acne risk (8.6% overall, up to 12.2% in high-risk subgroups).
What it foundPooled incidence of acne in IBD patients on JAK inhibitors was 8.6% (95% CI: 6.4%-11.6%), with higher rates for upadacitinib (12.2%) vs tofacitinib (2.6%) and filgotinib (2.3%), and in pediatric (12.2%) vs adult (7.4%) patients.
ContextConfirms and quantifies acne risk across JAK inhibitors in IBD, previously known from dermatology studies but not systematically assessed in this population.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakethe recommendation to use upadacitinib for induction and maintenance in patients previously exposed to anti-TNF

… MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. … The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Quraishi MN … Al-Bawardy B · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBD meta analysis · n=8,539 · Sep 1, 2026 · Inflamm Bowel Dis · IF 4.5

The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis.

New evidencesystematic reviewmeta-analysisepidemiology
Clinical takeawayConsider selective rather than routine CT imaging for IBD patients in the ED, as serious complications are uncommon.
What it foundPooled prevalence of serious penetrating IBD findings on ED CT was low: abscesses/inflammatory masses in 12% of CD and 3% of UC, perforations in 3% of CD and 1% of UC; non-IBD pathologies were <5%.
ContextChallenges current ED practice of frequent CT use in IBD by quantifying low yield for serious complications.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Decision at stakeuse of CT imaging in ulcerative colitis patients presenting to the emergency department

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Azward A … McCurdy JD · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBD prospective cohort · n=185 · Sep 1, 2026 · Inflamm Bowel Dis · IF 4.5

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

New therapyCrohn's diseasebiologicstherapeutic drug monitoring
Clinical takeawayConsider guselkumab as a long-term maintenance option for moderately to severely active Crohn's disease, including both biologic-naive patients and those with prior biologic failure, given its durable efficacy and favorable safety profile.
What it foundAt 5 years, 97.7% of guselkumab-treated patients with moderately to severely active Crohn's disease achieved clinical remission (as-observed), and 51.7% achieved endoscopic remission, with low rates of serious adverse events, discontinuations due to adverse events, and serious infections.
ContextGuselkumab, an IL-23p19 inhibitor, shows durable efficacy in Crohn's disease, extending prior phase 2 results to 5 years with a favorable safety profile. The study was not designed for statistical comparisons between groups.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeuse of guselkumab for induction and maintenance in moderately to severely active Crohn's disease

… MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. … Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Afzali A … GALAXI 1 investigators · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBD meta analysis · n=28,354 · Sep 1, 2026 · Inflamm Bowel Dis · IF 4.5

Incidence and predictors of surgical recurrence after primary ileocolic resection in Crohn ileitis: a systematic review and meta-analysis.

New evidenceCrohn's diseaseIBD surgerysystematic reviewmeta-analysis
Clinical takeawayCounsel post-resection Crohn patients that 5-year surgical recurrence risk is ~6% (1 in 17) in the biologics era, with no clear predictors to refine this estimate.
What it foundPooled 5- and 10-year surgical recurrence risks after primary ileocolic resection for Crohn disease were 5.7% (95% CI, 3.9-8.4) and 13.0% (8.3-19.7) in the biologics era (post-2000), a 3-fold decline from prior rates.
ContextRefines prior estimates by isolating ileocolic resections (65% of primary Crohn resections) and showing stable low recurrence since 2000, contradicting older mixed-resection data.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeendoscopic assessment at 6-12 months after surgically induced remission over no monitoring

… After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. … No recommendation on treating to endoscopic vs symptomatic remission. … Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Haanappel AEG … de Groof EJ · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink

Hepatology· 3

Hepatology systematic review · Sep 1, 2026 · Liver International · IF 6.7

Acceptability and Effectiveness of Point-of-Care HCV Testing in Low- and Middle-Income Countries: A Systematic Review.

New evidenceviral hepatitishealth servicessystematic review
Clinical takeawayConsider advocating for decentralized HCV testing models, including oral-based self-testing, in LMIC settings where centralized lab access is a barrier, particularly for high-risk populations.
What it foundIn LMICs, point-of-care HCV testing with onsite treatment achieved >90% testing/treatment uptake compared to centralized lab testing, and self-testing had 91%-99% acceptability in high-risk groups, with oral-based self-testing showing higher recommendation rates (94%-99%) than blood-based testing (86.1%).
ContextChallenges the reliance on centralized lab testing in LMICs, showing decentralized models can achieve high uptake where traditional systems fail.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA), "Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection" (Patients With Decompensated Cirrhosis section), 2023

Decision at stakethe use of point-of-care HCV testing in low- and middle-income countries

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnose active infection with HCV antibody testing with reflex HCV RNA PCR (Rating I, A); one-time opt-out anti-HCV testing is recommended for all adults ≥18 years and with each pregnancy (I, B), with annual testing for people who inject drugs, men with HIV who have unprotected sex with men, and MSM on PrEP (IIa, C). Treatment is recommended for all persons with acute or chronic HCV infection EXCEPT those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. Stage fibrosis noninvasively (FIB-4; biopsy not required). The simplified treatment algorithm applies only to treatment-naive adults and EXCLUDES prior HCV treatment, HBsAg positivity, current pregnancy, known or suspected HCC, prior liver transplantation, and any current or prior episode of decompensated cirrhosis; excluded patients are managed by the genotype/population-specific sections, not the simplified pathway. Treatment-naive WITHOUT cirrhosis (FIB-4 ≤3.25 and no other evidence of cirrhosis): glecaprevir 300 mg/pibrentasvir 120 mg once daily with food × 8 weeks, OR sofosbuvir 400 mg/velpatasvir 100 mg once daily × 12 weeks, both pangenotypic and equally recommended; pretreatment CBC, hepatic function panel, eGFR, quantitative HCV RNA, HIV, HBsAg, pregnancy test within 6 months, plus medication reconciliation for drug-drug interactions. Treatment-naive WITH compensated cirrhosis (Child-Pugh A): glecaprevir/pibrentasvir × 8 weeks for genotypes 1-6, OR sofosbuvir/velpatasvir × 12 weeks for genotypes 1, 2, 4, 5, and 6 only, in genotype 3 with compensated cirrhosis, baseline NS5A resistance testing is required before sofosbuvir/velpatasvir and the presence of Y93H changes the regimen; pretreatment labs within 3 months plus CTP score and liver ultrasound within 6 months. On treatment, no routine laboratory monitoring is required except counseling diabetic patients about hypoglycemia and monitoring INR in patients on warfarin. Decompensated cirrhosis (CTP class B or C, or any prior decompensation): refer to a practitioner with expertise, ideally at a liver transplant center; ALL protease-inhibitor-containing regimens (glecaprevir, grazoprevir, voxilaprevir) are contraindicated. Ribavirin-eligible, treatment-naive: sofosbuvir/velpatasvir + weight-based ribavirin × 12 weeks (all genotypes), or ledipasvir/sofosbuvir + ribavirin × 12 weeks for genotypes 1, 4, 5, 6; ribavirin-ineligible: sofosbuvir/velpatasvir (or ledipasvir/sofosbuvir for GT 1, 4, 5, 6) × 24 weeks without ribavirin; prior sofosbuvir-based or NS5A inhibitor-based treatment failure: sofosbuvir/velpatasvir + weight-based ribavirin × 24 weeks. In CTP class C, start ribavirin at 600 mg/day and increase as tolerated toward weight-based dosing. Cure is defined by quantitative HCV RNA undetectable ≥12 weeks after completing therapy (SVR12), checked with a hepatic function panel; patients without cirrhosis who achieve SVR need no further liver-related follow-up, while patients with cirrhosis continue HCC ultrasound surveillance every 6 months and variceal screening per AASLD guidelines after SVR. Repeat annual HCV RNA testing in anyone with ongoing exposure risk.

American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA), "Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection" (Patients With Decompensated Cirrhosis section), 2023 · reviewed 2026-07-23 ↗
Yee WL … Luchters S · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatology review · Sep 2, 2026 · J Hepatology · IF 40.1

Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.

New evidencehepatocellular carcinomabiomarkercost-effectivenesshealth services
Clinical takeawayConsider NC-aMRI as an alternative to ultrasound for HCC surveillance in patients with cirrhosis or high-risk chronic HBV (e.g., active hepatitis, family history of HCC), particularly where adherence or ultrasound sensitivity is a concern. Note: NC-aMRI avoids contrast but requires further validation for broader adoption. No clinical action yet for blood-based biomarkers: pending validation in prospective studies.
What it foundNon-contrast abbreviated MRI (NC-aMRI) showed superior sensitivity and specificity compared to ultrasound for HCC surveillance in recent trials.
ContextChallenges current guideline-recommended ultrasound + AFP surveillance, which has suboptimal sensitivity and lacks RCT evidence for mortality benefit. Proposes benefit stratification over risk stratification alone.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)

Decision at stakewhether to adopt abbreviated MRI or biomarker panels for HCC surveillance

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. … Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.

AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834) · reviewed 2026-10-25 ↗
Ioannou GN … Rowe IA · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
Hepatology prospective cohort · n=645 · Sep 1, 2026 · UEG Journal · IF 5.6

Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation.

New evidenceportal hypertensionliver transplantcirrhosis
Clinical takeawaymonitor platelet counts at 3 months post-LT as a marker of persistent portal hypertension and increased mortality risk
What it foundPersistent thrombocytopenia (< 110 G/L) at 3 months post-LT independently predicted mortality (aHR 2.31, 95% CI 1.01-5.30) after adjustment for MELD, age, CRP, and pre-LT TIPS.
ContextRecent literature from specialty journals suggests that the persistence of portal hypertension after liver transplantation may have a prognostic impact on post-transplant outcomes (pmid_42570327).
Measured against the standard of care· AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557)

Decision at stakemonitoring portal hypertension after liver transplantation

… SAAG ≥1.1 g/dL means portal hypertension (~97% accuracy). … Within high-SAAG ascites, total protein <2.5 g/dL suggests cirrhosis (also massive liver metastases or late Budd-Chiari). Total protein ≥2.5 g/dL suggests a cardiac or postsinusoidal cause (heart failure, portal vein thrombosis, SOS, early Budd-Chiari), so work up with echocardiography, hepatic-vein Doppler or right-heart catheterization. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform a diagnostic paracentesis as soon as possible in any patient with new-onset ascites that can be sampled. Also perform one in any patient with cirrhosis and ascites who is admitted to hospital. AASLD 2021 says this applies to emergent admission for any reason. AGA 2025 BPA 2 names admission for ascites- or encephalopathy-related symptoms. The tap rules out SBP even without signs of infection, because up to one-third of SBP is asymptomatic. Repeat it whenever signs, symptoms or labs suggest infection, and in tense ascites with AKI. Paracentesis is safe with coagulopathy: INR >1.5 or platelets <50×10^9/L is not a contraindication, and routine FFP or platelet transfusion is not recommended. Possible exceptions are DIC, and uremia with thrombocytopenia, where desmopressin may be considered. Initial fluid testing: neutrophil (PMN) count, total protein, and ascitic albumin with a same-day serum albumin to calculate the SAAG. AGA 2025 adds Gram stain and culture to the initial panel for new-onset ascites and hospitalized patients. AASLD 2021 treats culture as part of the SBP workup rather than the routine panel. Either way, inoculate ≥10 mL into aerobic and anaerobic blood-culture bottles at the bedside before antibiotics. Amylase, cytology, glucose, LDH, AFB/ADA and triglycerides are ordered only for a clinical reason. SAAG ≥1.1 g/dL means portal hypertension (~97% accuracy). SAAG <1.1 g/dL points to a non-portal-hypertensive cause: carcinomatosis, TB peritonitis, nephrotic syndrome, pancreatic or chylous ascites. Within high-SAAG ascites, total protein <2.5 g/dL suggests cirrhosis (also massive liver metastases or late Budd-Chiari). Total protein ≥2.5 g/dL suggests a cardiac or postsinusoidal cause (heart failure, portal vein thrombosis, SOS, early Budd-Chiari), so work up with echocardiography, hepatic-vein Doppler or right-heart catheterization. SBP is diagnosed by ascitic PMN >250/mm^3, with or without a positive culture, once a surgically treatable source has been excluded. SBE is diagnosed by pleural fluid PMN >250/mm^3 in a hepatic hydrothorax after pneumonia and other secondary causes are excluded. It is treated with antibiotics and no chest tube.

AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557) · reviewed 2026-10-11 ↗
Dominik N … Reiberger T · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink

Endoscopy· 3

Endoscopy rct · n=813 · Sep 1, 2026 · UEG Journal · IF 5.6

Acetate- Versus Lactate-Buffered Crystalloids for Prevention of Post-ERCP Pancreatitis in Patients Without Access to Rectal NSAIDs: A Multicentre Double-Blind Randomized Trial.

New evidenceERCPacute pancreatitisendoscopy quality
Clinical takeawayContinue using lactated Ringer's solution as the first-line crystalloid for aggressive hydration in patients at moderate-to-high PEP risk when rectal NSAIDs are unavailable.
What it foundPEP occurred in 12.4% of the LR group and 11.5% of the AC group (RR 0.93; 95% CI, 0.64-1.35; P=0.70), with no severe PEP or fluid overload.
ContextConfirms current practice: lactated Ringer's remains the preferred crystalloid for PEP prevention in settings without rectal NSAIDs.
Reinforcessuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

Decision at stakeusing lactated Ringer's solution for aggressive hydration to prevent post-ERCP pancreatitis

… Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Paik WH … Park DH · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy meta analysis · n=1,143 · Sep 1, 2026 · GIE · IF 8.0

Diagnostic Accuracy of the Endoscopic Grading of Gastric Intestinal Metaplasia for Detecting Extensive Disease: a Systematic Review and Meta-analysis.

New evidencesystematic reviewmeta-analysisbiomarkerendoscopy quality
Clinical takeawayConsider using EGGIM ≥5 during NBI/BLI endoscopy in adults undergoing upper gastrointestinal endoscopy to identify patients with extensive GIM (OLGIM III-IV) who may benefit from surveillance.
What it foundEGGIM cutoff ≥5 had 90% sensitivity and 92% specificity for detecting extensive GIM (OLGIM III-IV) compared to histological OLGIM staging, with a diagnostic odds ratio of 105.93 and AUC 0.96.
ContextConfirms EGGIM as a valid real-time endoscopic tool for risk stratification in gastric precancerous conditions, aligning with current interest in endoscopic staging over biopsy alone.
Reinforcessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34)

Decision at stakeusing the Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) score to risk-stratify patients

… Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform individual gastric risk assessment and staging of precancerous conditions at first-time gastroscopy, irrespective of the patient's country of origin. Use high quality endoscopy with virtual chromoendoscopy (VCE), after proper training, for screening, diagnosis and staging of atrophy and intestinal metaplasia and after endoscopic therapy; VCE guides the biopsy site, with random biopsies taken only when there are no endoscopically suspected changes. Take biopsies from at least two topographic sites, 2 from the antrum/incisura and 2 from the corpus, VCE-guided, in two separate, clearly labeled vials; an additional incisura biopsy is optional, not required. Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. Eradicate H. pylori in all patients with precancerous conditions and after endoscopic or surgical therapy. Discontinue or do not start gastric cancer screening or surveillance in asymptomatic individuals over 80, and weigh comorbidities when planning treatment of superficial lesions. Advise smoking cessation; low-dose daily aspirin may be considered for gastric cancer prevention only in selected individuals already at high cardiovascular risk. For visible neoplasia, use ESD for differentiated lesions clinically staged as dysplastic (low or high grade) or intramucosal carcinoma (any size if not ulcerated, or ≤30 mm if ulcerated), with EMR an alternative for Paris 0-IIa lesions ≤10 mm with low likelihood of malignancy. At the population level, endoscopic screening is suggested every 2-3 years in high-risk regions (age-standardized rate >20 per 100,000 person-years), every 5 years in intermediate-risk regions (ASR 10-20) only if cost-effectiveness has been proven, and not at all in low-risk regions (ASR <10).

European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34) · reviewed 2026-07-23 ↗
Luu MN … Quach DT · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy meta analysis · n=1,322 · Sep 1, 2026 · J Clin Gastro · IF 2.9

Performance, Efficacy, and Safety of Lubiprostone in Bowel Preparation Regimens: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

New evidencecolonoscopysystematic reviewmeta-analysis
Clinical takeawayConsider lubiprostone adjunct for patients undergoing colonoscopy, given its higher excellent prep rates without added risk, though it does not improve polyp detection.
What it foundLubiprostone adjunct bowel prep doubled excellent prep rates (OR 2.25, 95% CI 1.52-3.33) and reduced poor prep (P=0.009) compared to standard prep alone, with no difference in polyp detection, duration, or adverse events.
ContextConfirms lubiprostone's role in improving prep quality, a known challenge in colonoscopy, without altering detection or safety compared to standard prep.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wu Y … Han A · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink

Colorectal· 1

Colorectal prospective cohort · n=730 · Sep 3, 2026 · Am J Gastro · IF 9.8

Impact of Baseline Synchronous Adenoma Burden on the Risk of Metachronous Advanced Neoplasia.

New evidencecolorectal canceradenomacolorectal cancer screeningdysplasia
Clinical takeawayIn patients with a high-risk adenoma, use the presence of additional synchronous adenomas to identify a subgroup at particularly high risk for metachronous advanced neoplasia, reinforcing the importance of their recommended 3-year surveillance interval.
What it foundAmong patients with high-risk findings at baseline, the risk of metachronous advanced colorectal neoplasia was significantly elevated when a high-risk adenoma (HRA) was found with synchronous low-risk adenomas (aIRR 2.56) or with synchronous HRAs (aIRR 3.93), compared to having 3-4 low-risk adenomas alone.
ContextRefines current high-risk stratification by showing meta-ACRN risk is not uniform among conventionally 'high-risk' patients (3-10 LRAs or any HRA); synchronous adenoma burden drives heterogeneity.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

Decision at stakeassigning colonoscopy surveillance intervals based on polyp number, size, and histology

… Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. … Consider 3-year intervals if the burden is greatly reduced at surveillance. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Chang WY … Chiu HM · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Everything else this week79 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

IBD· 19

Hepatology· 23

Also screened this week64 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

Hepatology· 12

Pancreas/Biliary· 11

Endoscopy· 20

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.